Decitabine
Information
- Drug Name
- Decitabine
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| acute myeloid leukemia | DNMT3A MUTATION DNMT3A MUTATION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22124213 | Detail |
| ovarian cancer | DNMT1 EXPRESSION DNMT1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 25968887 | Detail |
| ovarian cancer | KRAS MUTATION KRAS MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25968887 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Among 46 AML patients treated with decitabine, the... | DNMT3A | DNMT3A MUTATION DNMT3A MUTATION | Sensitivity | true | CIViC Evidence | detail |
| DNMT1 expression (mRNA expression from an independ... | DNMT1 | DNMT1 EXPRESSION DNMT1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| KRAS mutation or amplification predicted sensitivi... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Decitabine induces TGFBI expression (by demethylat... | TGFBI | TGFBI EXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02172872 | Active, not recruiting | Phase 3 | "InDACtion" vs "3+7" Induction in AML | November 28, 2014 | December 2023 |
| NCT02085408 | Active, not recruiting | Phase 3 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 4, 2011 | October 2024 |
| NCT04277442 | Active, not recruiting | Phase 1 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | March 11, 2020 | June 4, 2025 |
| NCT04229979 | Active, not recruiting | Phase 3 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | February 8, 2021 | March 2025 |
| NCT04188405 | Active, not recruiting | Phase 2 | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | May 17, 2020 | September 1, 2024 |
| NCT03092674 | Active, not recruiting | Phase 2/Phase 3 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | February 2, 2018 | October 29, 2024 |
| NCT03404193 | Active, not recruiting | Phase 2 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | January 18, 2018 | December 31, 2024 |
| NCT05222984 | Active, not recruiting | Phase 1 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | July 29, 2022 | January 29, 2025 |
| NCT02890329 | Active, not recruiting | Phase 1 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | September 5, 2017 | July 1, 2024 |
| NCT03875287 | Active, not recruiting | Phase 1 | Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | April 17, 2019 | December 2024 |
| NCT03009240 | Active, not recruiting | Phase 1 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | August 21, 2017 | December 15, 2024 |
| NCT03026842 | Active, not recruiting | Phase 4 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | January 2017 | October 2024 |
| NCT03164057 | Active, not recruiting | Phase 2 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | June 15, 2017 | June 2027 |
| NCT04878432 | Active, not recruiting | Phase 2 | STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | March 17, 2022 | June 14, 2024 |
| NCT03445858 | Active, not recruiting | Early Phase 1 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | February 12, 2018 | January 12, 2025 |
| NCT04097470 | Active, not recruiting | Phase 2 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients | December 5, 2019 | November 2026 |
| NCT00095784 | Active, not recruiting | Phase 2 | Decitabine in Treating Patients With Myelofibrosis | September 29, 2004 | February 22, 2025 |
| NCT03017131 | Active, not recruiting | Phase 1 | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | December 8, 2017 | March 23, 2032 |
| NCT04874480 | Active, not recruiting | Phase 1 | Tegavivint for the Treatment of Relapsed or Refractory Leukemia | September 27, 2021 | December 30, 2024 |
| NCT04482621 | Active, not recruiting | Phase 2 | Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial | September 14, 2020 | March 2025 |
| NCT01861314 | Active, not recruiting | Phase 1 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | July 3, 2013 | March 7, 2025 |
| NCT02650986 | Active, not recruiting | Phase 1/Phase 2 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | July 14, 2017 | July 14, 2032 |
| NCT03226418 | Active, not recruiting | Phase 2 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | July 7, 2017 | October 7, 2024 |
| NCT02957968 | Active, not recruiting | Phase 2 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | January 24, 2017 | February 28, 2025 |
| NCT00416598 | Completed | Phase 2 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | November 15, 2006 | December 1, 2016 |
| NCT00477386 | Completed | Phase 1/Phase 2 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | July 2007 | September 2013 |
| NCT00479232 | Completed | Phase 1 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | June 2007 | March 2012 |
| NCT00492401 | Completed | Phase 2 | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | May 2007 | October 2014 |
| NCT00538876 | Completed | Phase 1 | Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | July 2007 | December 2009 |
| NCT00619099 | Completed | Phase 2 | A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | May 2008 | |
| NCT00671697 | Completed | Phase 1 | Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia | May 2008 | May 2011 |
| NCT00691938 | Completed | Phase 1/Phase 2 | LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | June 2008 | August 2014 |
| NCT00703300 | Completed | Phase 1 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | June 2008 | October 2014 |
| NCT00715793 | Completed | Phase 1/Phase 2 | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma | June 2008 | August 2015 |
| NCT00744757 | Completed | Phase 2 | An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) | August 2008 | August 2012 |
| NCT00760084 | Completed | Phase 2 | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | July 2005 | February 2008 |
| NCT00778375 | Completed | Phase 2 | Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | October 2008 | January 2015 |
| NCT00002832 | Completed | Phase 1/Phase 2 | Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | August 1995 | March 2002 |
| NCT00861874 | Completed | Phase 1 | A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia | January 2010 | |
| NCT00867672 | Completed | Phase 2 | Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia | August 2011 | February 2016 |
| NCT00882102 | Completed | Phase 2 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | April 2009 | August 2012 |
| NCT00903760 | Completed | Phase 2 | Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) | January 2010 | June 2015 |
| NCT00941109 | Completed | Phase 1 | Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) | December 2009 | September 2012 |
| NCT00968071 | Completed | Phase 2 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | February 2008 | August 2012 |
| NCT00986804 | Completed | Phase 1 | Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant | December 2009 | February 2016 |
| NCT01001143 | Completed | Phase 1 | Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) | May 2010 | May 2014 |
| NCT01098084 | Completed | Phase 2 | Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) | November 2008 | June 2009 |
| NCT01130506 | Completed | Phase 1 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 17, 2010 | |
| NCT01165996 | Completed | Phase 1/Phase 2 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | July 2010 | August 2012 |
| NCT01251627 | Completed | Phase 2 | Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia | April 2010 | June 2018 |
| NCT00000623 | Completed | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | July 2000 | July 2006 | |
| NCT01303796 | Completed | Phase 3 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia | October 1, 2011 | July 31, 2017 |
| NCT01352650 | Completed | Phase 1 | Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | June 17, 2011 | December 27, 2016 |
| NCT01375608 | Completed | Phase 2 | Decitabine for High-Risk Sickle Cell Disease | June 2011 | February 2016 |
| NCT01420926 | Completed | Phase 2 | Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia | November 16, 2011 | April 1, 2021 |
| NCT00002980 | Completed | Phase 1 | Decitabine in Treating Patients With Melanoma or Other Advanced Cancer | May 1997 | |
| NCT01546038 | Completed | Phase 2 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | June 27, 2012 | March 4, 2019 |
| NCT01567059 | Completed | Phase 2 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2012 | June 2013 |
| NCT01568333 | Completed | Phase 2 | A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia | August 2015 | August 2018 |
| NCT01593670 | Completed | Phase 2 | Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | March 2013 | October 23, 2018 |
| NCT01673217 | Completed | Phase 1 | Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | April 2009 | June 2013 |
| NCT01687400 | Completed | Phase 2 | Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | February 12, 2013 | November 13, 2017 |
| NCT01690507 | Completed | Phase 1/Phase 2 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | November 2012 | January 2016 |
| NCT01707004 | Completed | Phase 2 | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 16, 2013 | October 7, 2017 |
| NCT01720225 | Completed | Phase 2 | Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | November 6, 2012 | January 8, 2020 |
| NCT01729845 | Completed | Phase 1/Phase 2 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | December 20, 2012 | April 3, 2017 |
| NCT01786343 | Completed | Phase 2 | Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | February 5, 2013 | May 6, 2019 |
| NCT01794702 | Completed | Phase 1/Phase 2 | Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | February 20, 2013 | January 11, 2018 |
| NCT01798901 | Completed | Phase 1 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | September 17, 2013 | February 19, 2015 |
| NCT04146038 | Completed | Phase 2 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | October 26, 2020 | October 25, 2022 |
| NCT04086238 | Completed | Phase 1 | Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects | October 8, 2019 | November 30, 2019 |
| NCT01812252 | Completed | Phase 2 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | August 19, 2013 | October 26, 2022 |
| NCT01834248 | Completed | Phase 1 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | July 30, 2013 | March 21, 2016 |
| NCT04055844 | Completed | Phase 2 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | February 17, 2020 | September 6, 2022 |
| NCT03941964 | Completed | Phase 3 | A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | August 15, 2019 | March 14, 2022 |
| NCT01893320 | Completed | Phase 1/Phase 2 | Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | July 18, 2013 | January 11, 2021 |
| NCT01993641 | Completed | Phase 2 | Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA | December 2013 | June 2016 |
| NCT02441803 | Completed | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | September 14, 2015 | September 22, 2021 |
| NCT02959164 | Completed | Phase 1 | Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma | December 5, 2016 | October 16, 2020 |
| NCT00003361 | Completed | Phase 2 | Decitabine in Treating Patients With Myelodysplastic Syndrome | April 1998 | December 2009 |
| NCT00019825 | Completed | Phase 1 | Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura | October 1999 | |
| NCT00030615 | Completed | Phase 1 | Decitabine in Treating Patients With Advanced Solid Tumors | December 2001 | |
| NCT00037817 | Completed | Phase 1 | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | May 17, 2002 | November 9, 2009 |
| NCT00054431 | Completed | Phase 2 | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | January 2003 | |
| NCT00067808 | Completed | Phase 2 | Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) | October 2003 | May 2009 |
| NCT00075010 | Completed | Phase 1/Phase 2 | Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes | January 23, 2004 | November 8, 2006 |
| NCT00075634 | Completed | Phase 1 | Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma | December 2003 | |
| NCT00079378 | Completed | Phase 1 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 2004 | |
| NCT00084981 | Completed | Phase 1 | Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer | April 2004 | |
| NCT00085293 | Completed | Phase 2 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | May 2004 | May 2014 |
| NCT00109824 | Completed | Phase 1 | Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | March 2006 | |
| NCT00114257 | Completed | Phase 1 | Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders | May 2005 | |
| NCT00260065 | Completed | Phase 2 | A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes | May 2005 | December 2008 |
| NCT00275080 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | February 2006 | August 2014 |
| NCT00321711 | Completed | Phase 2 | Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents | October 1, 2006 | October 19, 2009 |
| NCT00349596 | Completed | Phase 1 | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | July 2006 | October 2014 |
| NCT00357708 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | June 2006 | |
| NCT00358644 | Completed | Phase 2 | Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | March 2005 | December 2008 |
| NCT00382200 | Completed | Phase 1/Phase 2 | Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes | July 2006 | January 5, 2023 |
| NCT00398983 | Completed | Phase 2/Phase 3 | Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | August 2006 | May 2012 |
| NCT00414310 | Completed | Phase 2 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | December 2006 | May 2015 |
| NCT03358719 | Completed | Phase 1 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | March 27, 2018 | August 25, 2021 |
| NCT03303339 | Completed | Phase 1/Phase 2 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | November 17, 2017 | November 17, 2021 |
| NCT02921061 | Completed | Phase 1/Phase 2 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | November 17, 2016 | October 24, 2018 |
| NCT03263936 | Completed | Phase 1 | Epigenetic Reprogramming in Relapse/Refractory AML | July 11, 2017 | February 10, 2022 |
| NCT02487563 | Completed | Phase 3 | Prospective Study of Patients With Thrombocytopenia Following HSCT | October 2015 | April 12, 2019 |
| NCT03066648 | Completed | Phase 1 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | July 6, 2017 | September 8, 2023 |
| NCT02632721 | Completed | Phase 1/Phase 2 | A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) | June 16, 2016 | January 16, 2023 |
| NCT03063944 | Completed | Phase 1 | STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | March 17, 2017 | March 4, 2024 |
| NCT02744742 | Completed | Phase 2/Phase 3 | G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT | April 18, 2016 | September 30, 2021 |
| NCT02996474 | Completed | Phase 1/Phase 2 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | December 16, 2016 | April 2, 2019 |
| NCT02846935 | Completed | Early Phase 1 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | April 25, 2017 | January 22, 2018 |
| NCT02847000 | Completed | Early Phase 1 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | December 20, 2016 | October 30, 2017 |
| NCT02878785 | Completed | Phase 1/Phase 2 | Decitabine and Talazoparib in Untreated AML and R/R AML | August 2016 | November 19, 2020 |
| NCT03828084 | Completed | Phase 1 | Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects | April 3, 2019 | May 3, 2019 |
| NCT02073838 | Completed | Phase 2 | Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | May 2015 | November 2022 |
| NCT02076191 | Completed | Phase 1/Phase 2 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | February 2014 | July 20, 2018 |
| NCT02084563 | Completed | Phase 2 | Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms | October 2012 | November 2016 |
| NCT02093403 | Completed | Phase 1 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | March 2014 | November 26, 2016 |
| NCT02109744 | Completed | Phase 1/Phase 2 | Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients | March 2014 | January 1, 2022 |
| NCT02121418 | Completed | N/A | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | June 2014 | February 14, 2018 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT03663751 | Completed | Phase 2 | Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation | July 1, 2018 | March 1, 2021 |
| NCT02190695 | Completed | Phase 2 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | April 1, 2013 | April 16, 2020 |
| NCT02214407 | Completed | Phase 3 | Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML | October 14, 2014 | August 16, 2021 |
| NCT02252107 | Completed | Phase 2 | 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 | October 2014 | May 2019 |
| NCT02257138 | Completed | Phase 1/Phase 2 | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | February 12, 2015 | March 19, 2021 |
| NCT02264873 | Completed | Phase 1 | Phase I, Dose Escalation Study of Decitabine | October 2014 | September 18, 2018 |
| NCT02316028 | Completed | Phase 1/Phase 2 | Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) | March 2014 | July 2017 |
| NCT02316964 | Completed | Phase 1 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | April 21, 2015 | December 20, 2019 |
| NCT02323607 | Completed | Phase 1 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | January 12, 2016 | July 12, 2018 |
| NCT01026376 | No longer available | An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) | June 2008 | November 2011 | |
| NCT05740449 | Not yet recruiting | Phase 1/Phase 2 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | October 1, 2023 | October 1, 2029 |
| NCT06445959 | Not yet recruiting | Phase 1/Phase 2 | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | November 29, 2024 | June 30, 2029 |
| NCT05766514 | Not yet recruiting | Phase 2 | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | June 2024 | December 2030 |
| NCT06441097 | Not yet recruiting | Phase 2 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | December 31, 2024 | December 31, 2027 |
| NCT06297772 | Not yet recruiting | Phase 3 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | June 1, 2024 | May 1, 2028 |
| NCT06383572 | Not yet recruiting | Phase 1/Phase 2 | Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | October 31, 2024 | April 1, 2029 |
| NCT05805072 | Not yet recruiting | N/A | Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | May 1, 2023 | June 30, 2024 |
| NCT05907499 | Not yet recruiting | Phase 3 | Decitabine for Poor Graft Function Post Allo-HSCT | July 1, 2023 | November 1, 2026 |
| NCT06129734 | Not yet recruiting | Phase 1/Phase 2 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | October 1, 2024 | December 31, 2025 |
| NCT05669079 | Not yet recruiting | Phase 3 | Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT | August 1, 2023 | November 1, 2026 |
| NCT04945096 | Not yet recruiting | Phase 3 | Outcomes of Patients After Allo-HSCT With Decitabine and NAC | July 1, 2021 | December 1, 2025 |
| NCT06401603 | Not yet recruiting | Phase 1 | A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | October 31, 2024 | January 1, 2029 |
| NCT04891757 | Recruiting | Phase 1 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | June 14, 2021 | June 2027 |
| NCT00801489 | Recruiting | Phase 2 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | April 4, 2007 | December 30, 2024 |
| NCT01515527 | Recruiting | Phase 2 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | February 7, 2012 | February 1, 2026 |
| NCT03041688 | Recruiting | Phase 1 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | February 8, 2018 | June 30, 2025 |
| NCT03132454 | Recruiting | Phase 1 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | July 25, 2017 | December 31, 2024 |
| NCT03240211 | Recruiting | Phase 1 | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | February 2, 2022 | December 31, 2025 |
| NCT03250962 | Recruiting | Phase 2 | SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma | September 11, 2017 | March 21, 2025 |
| NCT03418038 | Recruiting | Phase 2 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | March 23, 2018 | March 2026 |
| NCT03661307 | Recruiting | Phase 1/Phase 2 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | October 31, 2018 | January 1, 2026 |
| NCT03679650 | Recruiting | Phase 1 | Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients | October 11, 2018 | August 31, 2026 |
| NCT03793517 | Recruiting | Phase 2/Phase 3 | Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT | September 1, 2018 | October 2026 |
| NCT03844815 | Recruiting | Phase 1 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | November 18, 2019 | June 10, 2025 |
| NCT03855371 | Recruiting | Phase 1 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | January 10, 2018 | July 2024 |
| NCT03926624 | Recruiting | Phase 3 | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | November 22, 2019 | December 2022 |
| NCT03969446 | Recruiting | Phase 1 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | May 4, 2020 | November 4, 2025 |
| NCT03974217 | Recruiting | Phase 1 | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | August 1, 2019 | June 1, 2025 |
| NCT04187703 | Recruiting | Early Phase 1 | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | November 16, 2020 | December 1, 2025 |
| NCT04233294 | Recruiting | Phase 2 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | February 2, 2020 | February 2026 |
| NCT04245397 | Recruiting | Phase 1 | Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome | May 12, 2020 | March 2029 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT04337606 | Recruiting | Phase 1/Phase 2 | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | April 4, 2020 | April 4, 2026 |
| NCT04905810 | Recruiting | Phase 2 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | February 9, 2022 | December 1, 2025 |
| NCT05038592 | Recruiting | Phase 1/Phase 2 | Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia | March 4, 2022 | January 29, 2025 |
| NCT05184842 | Recruiting | Phase 2 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | March 23, 2022 | March 2025 |
| NCT05201066 | Recruiting | Phase 2 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | February 13, 2023 | February 14, 2028 |
| NCT05320640 | Recruiting | Phase 1/Phase 2 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | March 30, 2022 | April 1, 2025 |
| NCT05351346 | Recruiting | Phase 3 | Genotype-guided Treatment in DLBCL | June 1, 2022 | June 1, 2026 |
| NCT05382390 | Recruiting | Phase 3 | Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | January 21, 2022 | January 21, 2026 |
| NCT05455294 | Recruiting | Phase 1 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | July 18, 2022 | December 31, 2026 |
| NCT05564650 | Recruiting | Phase 1/Phase 2 | Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | January 12, 2023 | July 2025 |
| NCT05586074 | Recruiting | Phase 3 | HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | March 3, 2023 | May 14, 2026 |
| NCT05796570 | Recruiting | Phase 2 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies | April 19, 2023 | September 1, 2029 |
| NCT05799079 | Recruiting | Phase 2 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | January 29, 2024 | March 2029 |
| NCT05816356 | Recruiting | Phase 1 | To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males | March 24, 2023 | October 10, 2023 |
| NCT05829226 | Recruiting | Phase 1 | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | December 12, 2022 | May 2025 |
| NCT05983276 | Recruiting | Phase 2 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | November 16, 2023 | August 28, 2031 |
| NCT06156579 | Recruiting | Phase 2 | Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML | November 4, 2023 | March 4, 2025 |
| NCT06327685 | Recruiting | Phase 1 | Avapritinib With Decitabine in Patients With SM-AHN | March 13, 2024 | March 2027 |
| NCT06429098 | Recruiting | Phase 2 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | January 1, 2024 | December 31, 2027 |
| NCT04485052 | Suspended | Phase 1/Phase 2 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | September 25, 2020 | December 31, 2024 |
| NCT03184935 | Suspended | Phase 1/Phase 2 | Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) | December 31, 2024 | December 31, 2025 |
| NCT03021395 | Suspended | Phase 1/Phase 2 | Efficacy of Decitabine in Clearance of MRD | February 8, 2017 | December 2022 |
| NCT02203773 | Terminated | Phase 1 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | October 6, 2014 | June 16, 2022 |
| NCT02141477 | Terminated | Phase 1 | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | May 6, 2015 | June 22, 2017 |
| NCT00113321 | Terminated | Phase 2 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | March 2005 | November 2008 |
| NCT02029417 | Terminated | Phase 2 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2014 | December 2015 |
| NCT00748527 | Terminated | Phase 2 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | July 2007 | November 2010 |
| NCT02010645 | Terminated | Phase 2 | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | March 2014 | January 2, 2019 |
| NCT01882660 | Terminated | N/A | Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study | July 2013 | January 2018 |
| NCT00089089 | Terminated | Phase 1 | Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas | September 2004 | |
| NCT00701298 | Terminated | Phase 1 | Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors | April 2009 | |
| NCT04051996 | Terminated | Phase 2 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | December 6, 2019 | June 9, 2020 |
| NCT01846624 | Terminated | Phase 2 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | June 2013 | August 31, 2016 |
| NCT04113616 | Terminated | Phase 1/Phase 2 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | September 25, 2019 | September 27, 2023 |
| NCT00049582 | Terminated | Phase 1 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2002 | |
| NCT00561912 | Terminated | Phase 2 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | October 2007 | November 2009 |
| NCT00042796 | Terminated | Phase 1 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | December 2002 | |
| NCT01607645 | Terminated | Phase 2 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | July 2012 | September 2013 |
| NCT01011283 | Terminated | Phase 4 | To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. | November 2009 | |
| NCT00882206 | Terminated | Phase 2 | Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | April 2009 | January 2013 |
| NCT01498445 | Terminated | Phase 1/Phase 2 | An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) | June 12, 2012 | September 24, 2019 |
| NCT04854889 | Terminated | Phase 2 | Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia | April 22, 2021 | August 9, 2022 |
| NCT02954653 | Terminated | Phase 1 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | November 28, 2016 | December 5, 2017 |
| NCT02785900 | Terminated | Phase 3 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | May 2016 | October 3, 2017 |
| NCT01483690 | Terminated | Phase 1/Phase 2 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | December 2011 | July 31, 2015 |
| NCT03063203 | Terminated | Phase 2 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | July 14, 2017 | March 16, 2022 |
| NCT02634827 | Terminated | Phase 2 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | December 30, 2015 | June 12, 2018 |
| NCT02608268 | Terminated | Phase 1/Phase 2 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | November 23, 2015 | August 30, 2022 |
| NCT03113071 | Terminated | Phase 1/Phase 2 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | June 2, 2017 | March 11, 2019 |
| NCT01333449 | Terminated | Phase 2 | Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients | July 2010 | August 2013 |
| NCT03146871 | Terminated | Phase 2 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | April 20, 2017 | March 27, 2019 |
| NCT02532010 | Terminated | Phase 2 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML | June 15, 2015 | October 24, 2017 |
| NCT00791271 | Terminated | Phase 1 | Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | September 2, 2008 | May 2015 |
| NCT02469415 | Terminated | Phase 2 | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | September 30, 2015 | June 3, 2017 |
| NCT03295552 | Terminated | Phase 2 | Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC | November 15, 2017 | June 1, 2021 |
| NCT02412475 | Terminated | Phase 1 | Epigenetic Reprogramming in Relapse AML | February 21, 2015 | June 21, 2017 |
| NCT02343939 | Terminated | Phase 1/Phase 2 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | July 1, 2015 | February 21, 2019 |
| NCT02234037 | Terminated | Phase 1 | Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60 | November 2013 | May 2016 |
| NCT01177540 | Terminated | Phase 2 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | March 3, 2011 | July 19, 2013 |
| NCT04123392 | Unknown status | Phase 2/Phase 3 | Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT | October 2019 | September 2023 |
| NCT03356080 | Unknown status | Phase 2 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | July 7, 2017 | July 7, 2020 |
| NCT04353479 | Unknown status | Phase 2 | Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia | April 25, 2020 | December 31, 2022 |
| NCT03282825 | Unknown status | Phase 1 | Clinical Study of Decitabine and Paclitaxel Combination Therapy | March 28, 2017 | May 2018 |
| NCT03553537 | Unknown status | Phase 3 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | June 2018 | July 2021 |
| NCT01799083 | Unknown status | Phase 1/Phase 2 | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas | December 2012 | December 2017 |
| NCT01277484 | Unknown status | Phase 1 | Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML | January 2011 | December 2015 |
| NCT01633099 | Unknown status | Phase 3 | Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients | May 2012 | July 2016 |
| NCT01627041 | Unknown status | Phase 2 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | September 16, 2011 | |
| NCT03346642 | Unknown status | Phase 1/Phase 2 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | May 1, 2017 | October 1, 2019 |
| NCT03252457 | Unknown status | Phase 3 | Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP | September 1, 2018 | December 1, 2021 |
| NCT03080766 | Unknown status | Phase 2 | The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype | March 1, 2017 | December 28, 2021 |
| NCT04279379 | Unknown status | Phase 2 | Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | April 1, 2020 | December 31, 2022 |
| NCT04553393 | Unknown status | Phase 1/Phase 2 | Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden | September 9, 2020 | September 8, 2022 |
| NCT03381781 | Unknown status | Phase 2 | Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | March 2018 | November 2020 |
| NCT03558412 | Unknown status | Phase 4 | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma | June 1, 2018 | June 1, 2020 |
| NCT03579082 | Unknown status | Phase 4 | A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | June 1, 2018 | December 1, 2019 |
| NCT03596892 | Unknown status | Phase 2/Phase 3 | Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT | July 2018 | June 2022 |
| NCT02951728 | Unknown status | Phase 1/Phase 2 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma | October 2016 | October 2020 |
| NCT03687463 | Unknown status | Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia | April 10, 2015 | April 10, 2020 | |
| NCT00043134 | Unknown status | Phase 3 | Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome | May 2002 | |
| NCT03799224 | Unknown status | Phase 2/Phase 3 | Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia | December 1, 2018 | December 31, 2023 |
| NCT02961101 | Unknown status | Phase 1/Phase 2 | Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | May 2016 | May 2020 |
| NCT02985372 | Unknown status | Phase 3 | Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia | December 2016 | December 2019 |
| NCT01133886 | Unknown status | Phase 2 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure | September 2010 | September 2013 |
| NCT03467178 | Unknown status | Phase 2 | Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | July 30, 2018 | December 2021 |
| NCT02779569 | Unknown status | N/A | A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) | March 2016 | August 2019 |
| NCT02698124 | Unknown status | Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice | March 2016 | December 2022 | |
| NCT03530085 | Unknown status | Phase 2/Phase 3 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | June 15, 2018 | April 1, 2022 |
| NCT04025593 | Unknown status | Phase 2 | Biomarker Guided Treatment in DLBCL | July 17, 2019 | June 1, 2023 |
| NCT02685228 | Unknown status | N/A | Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer | March 2016 | December 2018 |
| NCT02488408 | Unknown status | Phase 1/Phase 2 | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | September 2014 | April 2022 |
| NCT01809392 | Unknown status | Phase 2/Phase 3 | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | January 2013 | December 2015 |
| NCT01806116 | Unknown status | Phase 4 | Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation | September 2009 | May 2014 |
| NCT04098653 | Unknown status | Phase 2/Phase 3 | Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT | September 2019 | August 2023 |
| NCT03045510 | Unknown status | Phase 2 | Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent | December 1, 2016 | July 30, 2020 |
| NCT04292769 | Unknown status | Phase 3 | Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors | January 21, 2020 | January 20, 2023 |
| NCT04493099 | Withdrawn | Phase 1/Phase 2 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | October 2020 | October 12, 2020 |
| NCT03377725 | Withdrawn | Phase 3 | Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) | March 20, 2018 | March 31, 2018 |
| NCT04655391 | Withdrawn | Phase 1 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | June 25, 2022 | December 15, 2023 |
| NCT04283526 | Withdrawn | Phase 1 | Study of Select Combinations in Adults With Myelofibrosis | November 30, 2020 | April 11, 2024 |
| NCT02564536 | Withdrawn | Phase 1 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | June 2017 | June 30, 2020 |
| NCT03709550 | Withdrawn | Phase 1/Phase 2 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | April 15, 2021 | April 15, 2024 |
| NCT06337331 | Withdrawn | Phase 2 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | August 31, 2024 | August 31, 2027 |
| NCT04985656 | Withdrawn | Phase 2 | A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | October 1, 2021 | November 8, 2024 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Dacogen
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2006
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- Phase I/II
- Target (Drug list of Screening Committee of Anticancer Drugs)
- DNMT
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 骨髄異形成症候群